What Progesterone Injection Treats: Main Uses and Benefits

The therapeutic scope of Progesterone Injection is used across therapeutic domains involving certain distressing symptoms, offering targeted symptomatic support across key gynecological and fertility domains.

---

Relief for Menstrual Cycle Symptom Burdens

This medication is commonly used across conditions presenting with acute episodes and characterized by episodic or fluctuating symptom patterns. It is relevant for easing symptoms in conditions like irregular or absent menstrual periods (amenorrhea) and abnormal uterine bleeding. It provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

---

Supportive Assistance in Fertility Treatments and Early Pregnancy

Applied in contexts where additional symptomatic support is needed, this medication is applied in addressing symptomatic needs in certain assisted reproductive technologies, such as In Vitro Fertilization (IVF), and is relevant in clinical settings that involve acute or unstable symptom patterns during early pregnancy. It is often used when symptoms intensify, providing temporary assistance in symptom stabilization and contributes to easing the overall symptom load and supports day-to-day comfort during periods of heightened physiological tension. “It helps address symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort.”

Quick Fact: Supports Management of Menstrual and Pregnancy-Related Symptoms

Regulatory References

1. NIH DailyMed label

Eligibility Map: Who Can and Cannot Use Progesterone Injection

This medicine is officially approved for use in women to treat amenorrhea (absence of menstruation) and abnormal uterine bleeding caused by hormonal imbalance, provided no organic pathology is present.

---

Contraindicated Populations (Must Not Use)

Progesterone Injection is strictly contraindicated and must not be used by individuals with certain pre-existing conditions, as outlined in regulatory documents. These include:

• Known or suspected pregnancy, or for use as a diagnostic test for pregnancy.
• Active or past history of thromboembolic disorders (e.g., blood clots) or cerebral vascular disease.
• Significant liver disease or liver dysfunction.
• Known or suspected malignancy of the breast or genital organs.
• Undiagnosed vaginal bleeding or known missed abortion.
• Known sensitivity or allergy to progesterone injection or its ingredients.

Restricted Use and Special Populations

Regulatory labeling highlights specific populations requiring careful observation and monitoring because safety and effectiveness are not fully established. These groups include patients with renal insufficiency and hepatic insufficiency (due to how the body processes the drug). Individuals with conditions that may be aggravated by fluid retention, such as epilepsy, migraine, asthma, or cardiac dysfunction, also require careful observation. The safety and effectiveness of the injection have not been established for use in pediatric or geriatric patients.

Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Progesterone Injection based primarily on its metabolic pathway and documented pharmacodynamic effects. No medicinal products are formally documented as contraindicated combinations due to an interaction mechanism.

---

Pharmacokinetic and Exposure Interactions

Co-administration with substances that affect the major metabolic enzyme CYP3A4 may alter Progesterone's plasma concentration. Inhibitors of this enzyme, such as Ketoconazole, Ritonavir, and Nelfinavir, are documented to increase Progesterone exposure. Conversely, inducers like Rifampicin, Phenytoin, and certain antiepileptic agents may accelerate its metabolism, leading to reduced Progesterone exposure. This reduction in exposure is also documented with herbal products containing St. John's wort.

Pharmacodynamic and Other Interactions

Progesterone may impact the activity of other medicines. It may cause a reduction in glucose tolerance, which requires consideration when co-administered with anti-diabetic agents. Furthermore, Progesterone may either enhance or reduce the effect of anticoagulants such as Coumarins. Progesterone is also documented to potentially raise the plasma concentration of the immunosuppressant Ciclosporin. Co-administration with ulipristal acetate is expected to result in reduced efficacy of Progesterone.

Population-Specific Notes

The need for caution and careful monitoring is officially documented for patients with renal insufficiency, as Progesterone metabolites are primarily excreted by the kidneys.

Progesterone injection exerts its effects through two principal, interconnected mechanistic domains.

Genomic Signaling via Nuclear Receptors

The primary mechanism involves progesterone acting as a specific agonist for the nuclear progesterone receptors (PR-A and PR-B). Upon ligand binding, the receptor complex translocates to the nucleus where it binds to Progesterone Response Elements (PREs) in the DNA. This interaction modulates the transcription of target genes, leading to changes in protein synthesis. These genomic effects drive long-term systemic physiological consequences, notably the maturation and transformation of the uterine lining (endometrium).

---

Rapid Effects via Membrane Signaling

The drug also engages in non-genomic signaling by interacting with membrane-associated progesterone receptors ( mPRs) and other surface targets. This mechanism rapidly modulates various intracellular signaling cascades, including the ERK, PI3K/Akt, and GABAA receptor pathways. These swift, non-transcriptional actions contribute to acute physiological consequences, such as stabilizing cellular membrane excitability and modulating smooth muscle contractility across various tissues.

Administration Overview

Progesterone injection is an oil-based solution intended for intramuscular administration. This means the medication must be delivered deep into the muscle tissue, typically in the buttocks or the outer thigh. Due to the viscosity of the oil carrier, the injection process requires specific preparation to ensure the medication is delivered effectively.

Preparation and Handling

The solution should be inspected visually for particulate matter or discoloration prior to use. Progesterone in oil can sometimes clarify or develop crystals if stored at cool temperatures; in such cases, warming the vial by rolling it between the palms of the hands may help dissolve any crystals before the dose is drawn into the syringe.

Injection Technique

To ensure the medication reaches the muscle layer, a needle of appropriate length is used. The skin at the injection site is typically pulled taut, and the needle is inserted at a 90-degree angle. Healthcare providers often recommend alternating the injection site between the left and right sides of the body to minimize local tissue irritation and allow the previous site to recover.

Post-Injection Care

After the needle is withdrawn, firm pressure may be applied to the site with a sterile gauze pad. Massaging the area gently after administration can help facilitate the absorption of the oil-based solution into the muscle tissue and may reduce the likelihood of local soreness or the formation of small lumps at the site of injection.

Research Evidence / Overview of Studies for Progesterone Injection

---

Evidence for Luteal Phase Support in Fertility Treatments

Progesterone Injection was studied for use in research exploring hormonal support during assisted reproductive procedures, such as In Vitro Fertilization (IVF). The research base features Randomized Controlled Trials (RCTs) and Systematic Reviews that examined women undergoing fertility treatments. These studies monitored key outcomes, including Live Birth Rate, Clinical Pregnancy Rate, and the measurement of progesterone concentrations in the blood. Research describes patterns related to pregnancy outcomes when the injection was studied in ART protocols, with some studies comparing it against other formulations of progesterone. Scientific discussion exists regarding the optimal route of administration, as many studies reported similar outcomes regardless of the progesterone delivery method.

---

Evidence for Menstrual Cycle Regulation

The use of Progesterone Injection for certain non-fertility indications, such as amenorrhea (absent periods) and abnormal uterine bleeding, was evaluated in Pivotal Clinical Trials that contributed to its original regulatory review. These studies examined adult women experiencing symptoms due to hormonal imbalance. Outcomes researchers studied were highly specific: the induction of withdrawal bleeding and the cessation of spontaneous bleeding over short, defined time intervals. Studies report how symptoms evolved in the observed populations, with findings describing the expected physiological response of the uterine lining. Follow-up durations were limited in these older studies, and there is limited information for long-term outcomes regarding the maintenance of a regular cycle.

---

The Study Landscape for Preterm Birth Prevention and Research Gaps

Research has also explored the use of injectable progestogens for the prevention of preterm birth in high-risk pregnant women, measuring outcomes like the rates of delivery before 37 weeks. Findings have been mixed, with some large trials reporting outcomes that did not demonstrate a specific difference compared to placebo for certain injectable progestogens. Studies suggest that results may vary significantly depending on the specific compound used. What remains uncertain is the drug's long-term effects, as many studies prioritize short-term responses. Data for certain special populations, such as those with significant comorbidities, remain insufficient.

Key Studies & References Australian public assessment report for progesterone (TGA) - (ART/Amenorrhea/Evidence Review)

Common questions about Progesterone Injection (FAQ)

---

Q: Can I take Progesterone Injection with a glass of wine?

Official product information cautions against the concurrent use of Progesterone Injection and alcohol. This is because alcohol may increase the drug's central nervous system (CNS) depressant effects, which could cause increased drowsiness or sedation. The regulatory caution notes a potential for increased risk of impaired ability to drive or operate machinery.

---

Q: How should Progesterone Injection be stored?

Official guidance recommends storing Progesterone Injection tablets at room temperature, which is typically between 20 C and 25 C (68 F and 77 F). To maintain effectiveness, the medication should be kept in its original container and protected from excess moisture and light.

---

Q: Does Progesterone Injection cause hair loss?

Official reports indicate that alopecia (hair loss) has been listed as a side effect reported during the post-marketing phase. However, this is considered a rare adverse reaction, and the exact frequency or certainty of the causal relationship is not fully established by the available regulatory data.

---

Q: Is it safe to take Progesterone Injection for longer than six months?

Clinical studies supporting the initial authorization of Progesterone Injection typically assessed patients for periods ranging from 12 to 16 weeks. According to official information, the safety profile of using this medication continuously for durations longer than six months has not been fully established by the labelled clinical trial data.

---

Q: Can children under 12 years old use Progesterone Injection?

Official product information specifies that the drug is authorized for use in adults (18 years and older) and adolescents (12 to 17 years). The official regulatory label specifies that use is not authorized for children under the age of 12 years.

---

Q: Does Progesterone Injection cause drowsiness or affect my sleep?

Regulatory information lists both drowsiness and insomnia as possible side effects. Official documents include a caution regarding tasks requiring mental alertness, such as driving or operating machinery, until a person knows how this medication might affect them.

The storage and disposal of Progesterone Injection are strictly defined by regulatory requirements.

---

Storage Requirements

• Temperature: Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Do not refrigerate.
• Protection: Vials must be stored in the original carton to protect the contents from light.
• Child Safety: Keep the medication and all associated materials out of the reach of children.
• Stability: If using a multi-dose vial, adhere to the manufacturer-established discard date for the opened container.

---

Disposal Instructions

• Sharps: All used and unused needles and syringes must be placed immediately into an FDA-approved sharps disposal container.
• Compliance: Any unused portion of the product must be discarded according to local laws and regulations for medication waste.